Astrazeneca Pharma India Limited · NSE:ASTRAZEN
Astrazeneca Pharma India — Shareholder Meeting (August 2024)
39 slides from Astrazeneca Pharma India's shareholder meeting presentation, Aug 8, 2024
Slide 1: 45th Annual General Meeting
45th Annual General Meeting Dr Sanjeev Panchal Managing Director, AZPIL 8th August 2024
Slide 2: Disclaimer
DISCLAIMER This presentation by AstraZeneca Pharma India Limited (the “Company”) is solely for general information purposes only and may not be taken away, distributed, reproduced, or passed on, directly or indirectly, to any other person or published in whole or in part, in any manner. This present
Slide 3: Board Structure
AstraZeneca Pharma India Limited Board Structure Ms. Revathy Ashok* Ms. Shilpa Divekar Nirula* Mr. Narayan K Director, Director, Audit Committee Chair & Seshadri* Nomination and Remuneration Risk Management Committee Chair Board Chairman Committee, Chair - Ms. Sylvia Varela Ms. Hooi Bien Chuah Mr. S
Slide 4: Agenda
Agenda Global Update Industry Overview AZPIL Update Oncology BioPharmaceuticals Rare Disease Digital Transformation & Healthcare Innovation Sustainability 4 Great Place to Work
Slide 5: Global Update
Global Update 5
Slide 6: AstraZeneca Global Year 2023 data
6 Source: AstraZeneca Global Year 2023 data
Slide 7: AstraZeneca Global H1 2024 results
Source: AstraZeneca Global H! 2024 results
Slide 8: India Market & Industry Overview
India Market & Industry Overview Dr Sanjeev Panchal M A N A G I N G D I R E C TO R
Slide 9: Country Macro Economic Environment
Country Macro Economic Environment India’s real GDP grew by 8.2% in FY 2023-24, 8.2% GDP Growth exceeding 8% in 3 of the 4 quarters [1] India is projected to be among the fastest- 3rd largest growing economies to 2030, to become the Economy world’s 3rd -largest economy [2] Ease of Improved in ease o
Slide 10: Fastest growing amongst top pharma companies
Fastest growing amongst top 10 pharma companies | +3 ranks IPM (domestic) is a $26.5 bn market, poised to grow at a CAGR of 8.7% between 2023-2026 $26.5 bn Source: IQVIA Mat Mar’24 10 YOY: Year on Year; MNCs: Multinational Companies; PSU: Public Sector Units; CAGR: Compound Annual Growth Rate;
Slide 11: Propelling our Growth Through Innovation strategy
Propelling our Growth Through Innovation strategy New launches Faster Partnership for early diagnosis • Oncology 9 regulatory approvals in FY • Biopharmaceuticals 2023-24 • Rare Disease (approved in 2022 and launched in 2023) MoU with Govt of Goa MoU with Govt of Karnataka Source: AstraZeneca Pharma
Slide 12: Bringing innovative medicines to India | Faster new assets
Bringing innovative medicines to India | Faster 6 new assets PROPEL BTC Deliver uHCC DB-03 DB-04 DG-02 Launched 12 Source: AstraZenca Pharma India Ltd AR 2023-24
Slide 13: AstraZeneca is amongst the fastest growing MNCs in IPM
AstraZeneca is amongst the fastest growing MNCs in IPM* Ranks 8th amongst MNCs in IPM2 Oncology business ranks 3rd in IPM1 propelling our growth Launched in April 6Fastest growing among No.1 Ovarian Cancer No.1 lung cancer Sustains its market 2021; is the No.1 leading Oncology brand & in top 10 bran
Slide 14: Continuing our strategic collaborations to further access
Continuing our strategic collaborations to further access – to be a Partner of choice Partnership with Partnership with Severe Asthma CoEs in CoE at Rajiv Gandhi Cancer Mankind Pharma Roche Diagnostics Goa, Mumbai Institute and Research Center (RGCI&RC) Source: AstraZenca Pharma India Ltd AR 2023-24
Slide 15: AstraZeneca India delivers strong double-digit growth
AstraZeneca India delivers strong double-digit growth Strong commercial performance and financial execution in FY 2023-24 % Sales by therapy area Total Revenue EPS 4.% +29% +63% 10.% Oncology Cardiovascular 24.% Diabetes 13303 64.6 62.% Respiratory 10291 39.7 FY 2022-23 FY 2023-24 FY 2022-23 FY 2023
Slide 16: AZ India Trailblazing the 'Pioneering in Science' Corporate Narrative
AZ India Trailblazing the ‘Pioneering in Science’ and bringing ‘Innovative Medicines’ to India Corporate Narrative 16 Source: Stories in the media-publicly available
Slide 17: Winning accolades
Winning accolades 2023: Great Place to Work’ 2022-23: ET 2023: AsiaOne G20 2023: Times Now 2024: ESG Champions Certified” Best Healthcare Healthcare Commitment 'Impactful CEOs’ Sixth time in a row! of India 2024 in Brands award Award as a testament to Sanjeev Panchal was Recognised among 100 Best Bi
Slide 18: Oncology
AstraZeneca Oncology
Slide 19: Our Oncology business is accelerating towards #1 position
Our Oncology business is accelerating towards #1 position Supported by Innovative Science IPSOS GR% (MAT DEC 23 vs MAT DEC 22) Value in INRm GR% 3,199 46% 42% 2,007 99% 21% 15% 14% 1,313 0% AZ Market 473 0% Top 10 MNC Top 10 Overall AZ Rank MAT Dec’23 3 316 NA (1) IPSOS, MAT Dec’23 19 (2) Internal R
Slide 20: Committed to transforming patient outcomes
Committed to transforming patient outcomes Transforming Embracing Strengthening Innovative Access Diagnostics Digital Partnerships Programs • India as Hub of Molecular Dx • IHW forums – Drive awareness • Technology: qure.ai, Alveofit, • Patient Support Program: on disease areas TriCOG SAHAY, Patient
Slide 21: Biopharmaceuticals
Astrazeneca? Biopharmaceuticals
Slide 22: BioPharmaceuticals Business continues to grow
BioPharmaceuticals Business continues to grow BBU TA Performance % Sales by brands 8% 4129 Brilinta 3835 14% Fasenra 13% 39% Forxiga Crestor 4% Symbicort 9% 24% Seloken 5% 409 16% 329 Other Brands CVRM R&I 2022-23 2023-24 CVRM portfolio grew by 8% despite of headwinds from generic brands. R&I expand
Slide 23: Stepping up Patient Centricity & Awareness
Stepping up Patient Centricity & Awareness •Community Education •Digital Cardiac •Patient Education 120+ centers activated through Social media | Rehabilitation for Heart Programs covering 50 300,000 Active Followers. Attack & Heart Failure Topics across CVRM ~55,000 Patients screened Patients. Dise
Slide 24: Rare Disease
Astrazeneca Rare Disease
Slide 25: Early Diagnosis and Access for Rare Diseases in India
Early Diagnosis and Access for Rare Diseases in India Launched the first and only Race for Seven with ORDI- Roundtable with FICCI to approved therapy for the largest PAG on RD in India to widen the ambit of the treatment of pediatric patients build awareness diseases included in the with neurofibrom
Slide 26: Commemorating Rare Disease Day with Sweden Embassy
Commemorating Rare Disease Day with Sweden Embassy Mobilizing influencers in the country to augment need for NPRD and inclusion of more diseases in India 26
Slide 27: Digital Transformation & Healthcare Innovation
Digital Transformation & Healthcare Innovation
Slide 28: Transforming patient lives by accelerating Digital adoption
Transforming patient lives by accelerating Digital adoption A digital ecosystem powered by AI, Innovation, Analytics & Insights to effectively engage HCPs and patients Digital & AI Accelerate delivery & innovation Analytics & Insights 5000+ whitespace HCPs AR tool for NF1 Awareness & Enpire enhancem
Slide 29: Sustainability
AstraZeneca Sustainability a Wurth Proginimg
Slide 30: Community Engagement
Community Engagement Ganga Godavari Cancer Screening • Screened over 10,000 Program women across 125+ (screening women for oral, breast camps across Delhi, Nasik, and cervical cancer) and Patna • Reached over 95,000 youth • Trained 145 youth as peer Young Health Program educators • Engaged 28 govern
Slide 31: AZ Forest- Global program
AZ Forest- Global program 'Regeneration Meghalaya' is a commitment to plant hope, nurture sustainability, and grow a future where nature and agriculture thrive in harmony. 30-year regenerative horticulture and agriculture project in Meghalaya Plantation of 64 million trees, restoring 22,670 he
Slide 32: Great Place to Work
Astrazeneca Great Place to Work
Slide 33: Our GPTW Strategy is aligned to People development
Our GPTW Strategy is aligned to People development INTERNAL PULSE SURVEY 89% 89% 87% 90% Managers in my Employees believe AZ Employees believe Employees believe strongly function/company are demonstrates a commitment to AZ is a great place to in AstraZeneca's future committed to diversity and the sa
Slide 34: Our purpose
Inspired by our purpose and values, we’re transforming the future of healthcare by unlocking the power of what science can do – for people, society and the planet. Our purpose We push the boundaries of science to deliver life-changing medicines 34
Slide 35: Years of AstraZeneca
YEARS OF AstraZeneca
Slide 36: Access the milestone book through our website
You can access the milestone book through our 36 website: astrazeneca.in
Slide 37: Our Focus
Our Focus Growth Through Expanding pipeline Patient Centricity We are Accelerating Innovation across all our TA- is central to accelerating our Ambition Zero strategy | Science & everything we do | Talent & Carbon Oncology, Access Continue Development Biopharmaceutical, partnering with agenda Rare D
Slide 38: Thank you for your guidance and support
Thank you for your guidance and support for the past 12 years 38
Slide 39: Thank you
Thank you 39
AstraZeneca Pharma India — Shareholder Meeting (August 2024) on 6ix